EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Catalent, Inc. is a holding company ... and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer ...
Catalent (CTLT) issued the following open letter to customers: “I want to correct a few key inaccuracies that have been reported in the press regarding Novo Holdings’ pending acquisition of ...
Nov 5 (Reuters) - Contract drug manufacturer Catalent (CTLT.N), opens new tab, which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below ...
Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report ... and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment ...
The firms entered into a merger agreement in February for Novo Holdings to acquire Catalent in an all-cash transaction worth $16.5 billion. That deal still expects to close toward the end of ...
Catalent CTLT recently announced that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ, to Ardena. Ardena is a ...
Catalent, a leading contract drug manufacturer, issued an open letter on Monday to reassure customers that a proposed $16.5 billion deal — in which it would be acquired by Novo Nordisk’s ...
Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition Roche reported a 9% increase in third-quarter sales, driven by strong ...
The "gel" she's referring to? The adhesive; We recommend: Aprés Extend Gel, Dashing Diva GelXtend Max Comfort Soft Gel Glue, ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...